Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:30:10 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:ARDX from 2023-05-04 to 2024-05-03 - 45 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:02U:ARDXNews ReleaseArdelyx Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-01 08:00U:ARDXNews ReleaseArdelyx to Present Additional Data Supporting First-In-Class XPHOZAH(TM) (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
2024-04-18 08:00U:ARDXNews ReleaseArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024
2024-03-28 16:05U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2024-03-25 08:00U:ARDXNews ReleaseArdelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
2024-03-12 16:35U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2024-02-27 08:00U:ARDXNews ReleaseArdelyx to Participate at the Cowen 44th Annual Health Care Conference
2024-02-22 16:01U:ARDXNews ReleaseArdelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-01 08:00U:ARDXNews ReleaseArdelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
2024-01-12 07:56U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2024-01-08 08:00U:ARDXNews ReleaseArdelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
2024-01-03 08:03U:ARDXNews ReleaseArdelyx to Provide Company Update on IBSRELA ‚ ® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
2023-12-20 08:00U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-11-21 16:02U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-11-21 08:02U:ARDXNews ReleaseArdelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
2023-11-15 16:02U:ARDXNews ReleaseXPHOZAH ‚ ® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
2023-11-13 16:02U:ARDXNews ReleaseArdelyx Announces Departure of Board Member
2023-11-10 08:05U:ARDXNews ReleaseArdelyx to Participate at the Jefferies London Healthcare Conference
2023-11-06 08:00U:ARDXNews ReleaseArdelyx Announces XPHOZAH ‚ ® (tenapanor) Now Available in the United States
2023-11-03 08:00U:ARDXNews ReleaseArdelyx Shares Positive Data from Studies of XPHOZAH ‚ ® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
2023-10-31 07:00U:ARDXNews ReleaseArdelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA ‚ ® Net Sales Revenue Guidance
2023-10-30 17:43U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-10-23 08:07U:ARDXNews ReleaseArdelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA ‚ ® (tenapanor) for ‚  IBS-C and hosts IBS-C Product Theater at ACG 2023
2023-10-18 16:03U:ARDXNews ReleaseArdelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
2023-10-17 19:24U:ARDXNews ReleaseArdelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
2023-10-17 19:01U:ARDXNews ReleaseFDA Approves XPHOZAH ‚ ® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
2023-10-13 08:00U:ARDXNews ReleaseArdelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
2023-10-04 08:00U:ARDXNews ReleaseArdelyx Shares Preliminary Data on Use of IBSRELA ‚ ® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
2023-09-28 08:02U:ARDXNews ReleaseArdelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
2023-09-25 04:15U:ARDXNews ReleaseTenapanor for Hyperphosphatemia Approved in Japan
2023-09-11 08:00U:ARDXNews ReleaseArdelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA ‚ ® (tenapanor) for ‚  IBS-C at GHAPP 2023
2023-09-08 08:00U:ARDXNews ReleaseArdelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-07 08:00U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-08-02 07:00U:ARDXNews ReleaseArdelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
2023-07-27 16:05U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-07-26 07:55U:ARDXNews ReleaseArdelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-07-20 16:05U:ARDXNews ReleaseArdelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
2023-07-13 08:00U:ARDXNews ReleaseArdelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
2023-06-29 16:09U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-06-05 08:00U:ARDXNews ReleaseLeading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
2023-05-31 08:00U:ARDXNews ReleaseArdelyx to Present at the Jefferies 2023 Healthcare Conference
2023-05-23 16:05U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-05-17 07:30U:ARDXNews ReleaseArdelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH ‚ ® (tenapanor)
2023-05-15 16:05U:ARDXNews ReleaseArdelyx, Inc. Reports Employment Inducement Grants
2023-05-09 08:00U:ARDXNews ReleaseArdelyx Presents Positive Data at DDW 2023 on IBSRELA ‚ ® (tenapanor), a First-In-Class Treatment for IBS-C in Adults